2020 Study on Breast Cancer, Broccoli, and Sulforaphane
Exciting epidemiological studies show that a high level of cruciferous vegetable intake might lower the risk of breast cancer.
Rong et al. (2020) show that Sulforaphane (SFN), which is abundant in broccoli and broccoli sprouts, acts as an inhibitor of enzymes involved in carcinogen activation to inhibit proliferation and induce apoptosis of cancer cells.
This means that regular consumption of bioactive nutritional compounds like Sulforaphanes can alter the epigenome, playing an active role in cancer prevention and therapy (Rong et al., 2020).
Sulforaphane (SFN) is a compound derived from cruciferous plants shown to be effective in cancer prevention and suppression. Myeloid-derived suppressor cells (MDSCs) are known to inhibit anti-tumor immunity; however, whether SFN regulates the anti-tumor activity of MDSCs in breast cancer is still unknown. In the current study, we found that SFN blocked prostaglandin E2 (PGE2) synthesis in parental and doxorubicin (DOX)-resistant breast cancer 4T1 cell lines by activating NF-E2-related factor 2 (Nrf2). Nrf2-mediated reduction of PGE2 was dependent on the enhanced expression of heme oxygenase 1 (HO-1) and glutamate-cysteine ligase (GCLC), and decreased COX-2 expression in breast cancer cells. Moreover, our study further revealed that reduced PGE2 secretion from SFN-treated 4T1 cells triggered MDSCs to switch to an immunogenic phenotype, enhancing the anti-tumor activities of CD8+T cells. Co-administration of SFN and DOX was more efficacious for the treatment of breast cancer in a mouse model than either agent alone, as evidenced by the significant decrease in tumor volume, MDSC expansion, and increase in cytotoxic CD8+T cells. Taken together, our data indicate that SFN reverses the immunosuppressive microenvironment and is a potent adjuvant chemotherapeutic candidate in breast cancer. Article
The study demonstrated that the adjuvant adminis-tration of SFN blocked MDSC accumulation and suppressive activities by inhibiting COX-2-mediated PGE2 secretion, enhancing the therapeutic effects of DOX against breast cancer. There are also promising results of SFN administration for cancer, chronic obstructive pulmonary disease, autism, and inflammatory diseases in several clinical studies, wherein the molecule seems to be well-tolerated without clinically significant adverse effects . Therefore, SFN could be used as a promising adjuvant therapeutic agent to DOX, and future clinical trials are needed to ascertain its possible beneficial effects.
Broccoli sprouts are the richest source of glucoraphanin which is the direct precursor to Sulforaphane. Broccoli sulforaphane is one of the most potent inducers of phase II enzymes. Our Glucosinolates & Sulforaphanes is a powerhouse, providing a four fold increase in the phase 2 enzyme potential.
Glucosinolates & Sulforaphanes
Rong, Y., Huang, L., Yi, K., Chen, H., Liu, S., Zhang, W., ... & Wang, F. (2020). Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells. Cancer Letters, 493, 189-196. Article
We have developed our products based on scientific research and/or the practical experience of many healthcare practitioners. There is a growing body of literature on food based nutrition and supplements and their application in support of our health. Please use our products under the advisement of your doctor.
New Dietary Guidelines from USA Government: Dietary-Guidelines-2020-2025
©2005 - 2021 BioImmersion Inc. All Rights Reserved